{"id":40282,"date":"2025-08-28T13:34:34","date_gmt":"2025-08-28T05:34:34","guid":{"rendered":"https:\/\/flcube.com\/?p=40282"},"modified":"2025-08-28T13:34:35","modified_gmt":"2025-08-28T05:34:35","slug":"immuneonco-secures-5-m-milestone-from-instil-bio-strengthening-axion-bio-collaboration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40282","title":{"rendered":"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration"},"content":{"rendered":"\n<p>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/1541:HKG\">HKG: 1541<\/a>) on Aug 28, 2025 announced the receipt of a <strong>$5\u202fmillion<\/strong> milestone payment from its partner, <strong>Instil Bio, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/TIL:NASDAQ\">NASDAQ: TIL<\/a>). The payment, the third in the development timeline, was made on schedule under the licensing and collaboration agreement for the oncology candidates <strong>IMM2510<\/strong> and <strong>IMM27M<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-partnership-snapshot\">Partnership Snapshot<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Partner<\/strong><\/td><td>Instil Bio, Inc.<\/td><\/tr><tr><td><strong>Milestone Payment<\/strong><\/td><td><strong>$5\u202fM<\/strong> (3rd milestone)<\/td><\/tr><tr><td><strong>Agreement Scope<\/strong><\/td><td>Licensing &amp; collaboration for <strong>IMM2510<\/strong> &amp; <strong>IMM27M<\/strong><\/td><\/tr><tr><td><strong>Previous Deal<\/strong><\/td><td>$2\u202fB collaboration with <strong>Axion Bio, Inc.<\/strong> (formerly SynBioTx) \u2013 grants global rights outside Greater China<\/td><\/tr><tr><td><strong>ImmuneOnco Rights<\/strong><\/td><td>Full rights within Greater China; upfront + near\u2011term payments of $50\u202fM<\/td><\/tr><tr><td><strong>Future Revenue<\/strong><\/td><td>Up to $2\u202fB in development, regulatory, and commercial milestones; royalties on sales outside Greater China (single\u2011digit to low double\u2011digit percentages)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Cash Flow<\/strong> \u2013 $5\u202fM boost enhances liquidity for ongoing clinical programs.<\/li>\n\n\n\n<li><strong>Revenue Trajectory<\/strong> \u2013 Potential additional $2\u202fB in milestone payments and royalty streams as IMM2510\/IMM27M progress to regulatory approval and market launch.<\/li>\n\n\n\n<li><strong>Balance\u2011Sheet Position<\/strong> \u2013 Strengthens working capital and supports downstream R&amp;D investments.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Development<\/strong> \u2013 The milestone payment confirms that IMM2510 and IMM27M are on track to meet key developmental milestones, reducing time\u2011to\u2011market risk.<\/li>\n\n\n\n<li><strong>Global Reach<\/strong> \u2013 The Axion Bio partnership secures commercial rights across all territories outside Greater China, positioning ImmuneOnco for a truly global launch.<\/li>\n\n\n\n<li><strong>Revenue Diversification<\/strong> \u2013 Dual revenue streams from upfront\/near\u2011term payments and future milestones\/royalties create a sustainable, self\u2011sufficient business model.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-outlook\">Outlook<\/h3>\n\n\n\n<p>ImmuneOnco\u2019s management remains optimistic about the commercial prospects of IMM2510 and IMM27M. The company plans to capitalize on the partnership\u2019s global footprint, while continuing to expand its pipeline within Greater China. Investors should monitor milestone attainment and regulatory approvals, which will determine the pace of subsequent revenue realization.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (HKG: 1541) on Aug 28, 2025 announced the receipt of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40284,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1028,229,3830,1029],"class_list":["post-40282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-hkg-1541","tag-immuneonco-biopharmaceuticals","tag-instil-bio","tag-nasdaq-til"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hong Kong\u2011listed ImmuneOnco Biopharmaceuticals (HKG: 1541) has received a third milestone payment of $5\u202fM from Instil Bio for its IMM2510\/IMM27M partnership. The payment follows a $2\u202fB collaboration with Axion Bio that grants global rights outside Greater China, positioning ImmuneOnco for robust revenue upside.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40282\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration\" \/>\n<meta property=\"og:description\" content=\"Hong Kong\u2011listed ImmuneOnco Biopharmaceuticals (HKG: 1541) has received a third milestone payment of $5\u202fM from Instil Bio for its IMM2510\/IMM27M partnership. The payment follows a $2\u202fB collaboration with Axion Bio that grants global rights outside Greater China, positioning ImmuneOnco for robust revenue upside.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40282\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T05:34:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-28T05:34:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2803.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration\",\"datePublished\":\"2025-08-28T05:34:34+00:00\",\"dateModified\":\"2025-08-28T05:34:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282\"},\"wordCount\":310,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2803.webp\",\"keywords\":[\"HKG: 1541\",\"ImmuneOnco Biopharmaceuticals\",\"Instil Bio\",\"NASDAQ: TIL\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40282#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40282\",\"name\":\"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2803.webp\",\"datePublished\":\"2025-08-28T05:34:34+00:00\",\"dateModified\":\"2025-08-28T05:34:35+00:00\",\"description\":\"Hong Kong\u2011listed ImmuneOnco Biopharmaceuticals (HKG: 1541) has received a third milestone payment of $5\u202fM from Instil Bio for its IMM2510\\\/IMM27M partnership. The payment follows a $2\u202fB collaboration with Axion Bio that grants global rights outside Greater China, positioning ImmuneOnco for robust revenue upside.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40282\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2803.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2803.webp\",\"width\":1080,\"height\":608,\"caption\":\"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40282#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration - Insight, China&#039;s Pharmaceutical Industry","description":"Hong Kong\u2011listed ImmuneOnco Biopharmaceuticals (HKG: 1541) has received a third milestone payment of $5\u202fM from Instil Bio for its IMM2510\/IMM27M partnership. The payment follows a $2\u202fB collaboration with Axion Bio that grants global rights outside Greater China, positioning ImmuneOnco for robust revenue upside.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40282","og_locale":"en_US","og_type":"article","og_title":"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration","og_description":"Hong Kong\u2011listed ImmuneOnco Biopharmaceuticals (HKG: 1541) has received a third milestone payment of $5\u202fM from Instil Bio for its IMM2510\/IMM27M partnership. The payment follows a $2\u202fB collaboration with Axion Bio that grants global rights outside Greater China, positioning ImmuneOnco for robust revenue upside.","og_url":"https:\/\/flcube.com\/?p=40282","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-28T05:34:34+00:00","article_modified_time":"2025-08-28T05:34:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2803.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40282#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40282"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration","datePublished":"2025-08-28T05:34:34+00:00","dateModified":"2025-08-28T05:34:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40282"},"wordCount":310,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40282#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2803.webp","keywords":["HKG: 1541","ImmuneOnco Biopharmaceuticals","Instil Bio","NASDAQ: TIL"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40282#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40282","url":"https:\/\/flcube.com\/?p=40282","name":"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40282#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40282#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2803.webp","datePublished":"2025-08-28T05:34:34+00:00","dateModified":"2025-08-28T05:34:35+00:00","description":"Hong Kong\u2011listed ImmuneOnco Biopharmaceuticals (HKG: 1541) has received a third milestone payment of $5\u202fM from Instil Bio for its IMM2510\/IMM27M partnership. The payment follows a $2\u202fB collaboration with Axion Bio that grants global rights outside Greater China, positioning ImmuneOnco for robust revenue upside.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40282#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40282"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40282#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2803.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2803.webp","width":1080,"height":608,"caption":"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40282#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ImmuneOnco Secures $5\u202fM Milestone from Instil Bio, Strengthening Axion Bio Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2803.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40282"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40282\/revisions"}],"predecessor-version":[{"id":40285,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40282\/revisions\/40285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40284"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}